CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
TW254946B
(US07585860-20090908-C00112.png)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
ZA956029B
(en)
|
1994-07-22 |
1997-01-20 |
Lilly Co Eli |
Combination treatment for inhibiting bone loss
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
EP0860433B1
(en)
|
1995-11-07 |
2002-07-03 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
PL201475B1
(pl)
|
1998-09-29 |
2009-04-30 |
Wyeth Corp |
Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
KR20020071931A
(ko)
|
2000-01-07 |
2002-09-13 |
트렌스폼 파마수티컬스 인코퍼레이티드 |
다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
US6511986B2
(en)
|
2000-08-11 |
2003-01-28 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
ES2312568T3
(es)
|
2001-04-06 |
2009-03-01 |
Wyeth |
Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo.
|
TWI233359B
(en)
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
TWI296196B
(en)
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
US20020198137A1
(en)
|
2001-06-01 |
2002-12-26 |
Wyeth |
Antineoplastic combinations
|
NZ529877A
(en)
|
2001-06-01 |
2006-08-31 |
Wyeth Corp |
Antineoplastic combinations
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
RU2309150C2
(ru)
|
2001-11-27 |
2007-10-27 |
Уайт Холдингз Корпорейшн |
3-цианохинолины в качестве ингибиторов egf-r и her2 киназ
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
BR0311814A
(pt)
|
2002-06-05 |
2005-03-15 |
Cedars Sinai Medical Center |
Método de tratar câncer empregando inibidores de cinase
|
AU2003248813A1
(en)
|
2002-07-05 |
2004-01-23 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
US20040209930A1
(en)
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
BRPI0409632A
(pt)
|
2003-04-22 |
2006-04-25 |
Wyeth Corp |
combinações antineoplásticas
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
NZ580384A
(en)
|
2003-07-23 |
2011-03-31 |
Bayer Pharmaceuticals Corp |
4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
WO2005018677A2
(en)
|
2003-08-01 |
2005-03-03 |
Wyeth Holdings Corporation |
Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
|
JP2007502819A
(ja)
|
2003-08-19 |
2007-02-15 |
ワイス・ホールディングズ・コーポレイション |
4−アミノ−3−キノリンカルボニトリルの調製方法
|
US7399865B2
(en)
*
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
BR0318503A
(pt)
|
2003-09-15 |
2006-09-12 |
Wyeth Corp |
quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
EP1756137A4
(en)
|
2003-11-05 |
2007-10-31 |
Univ Texas |
DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
JP4350148B2
(ja)
|
2004-03-31 |
2009-10-21 |
ザ ジェネラル ホスピタル コーポレイション |
上皮細胞成長因子受容体ターゲティング治療に対する癌の応答性を決定する方法
|
BRPI0513589A
(pt)
|
2004-07-23 |
2008-05-13 |
Astrazeneca Ab |
método para selecionar um mamìfero tendo ou suspeito de ter um tumor para tratamento com uma droga de receptor de erbb
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
BRPI0516592A
(pt)
|
2004-10-13 |
2008-09-23 |
Wyeth Corp |
composto de fórmula
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
CN102886045A
(zh)
|
2005-02-03 |
2013-01-23 |
综合医院公司 |
治疗吉非替尼耐药性癌症的方法
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
PT1859793E
(pt)
|
2005-02-28 |
2011-07-05 |
Eisai R&D Man Co Ltd |
Uso combinado inovador de um composto de sulfonamida no tratamento oncológico
|
CA2599445C
(en)
|
2005-03-09 |
2022-05-03 |
Abbott Laboratories |
Diagnostics method for identifying candidate patients for the treatment with trastuzumab
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
CA2646257A1
(en)
|
2005-04-14 |
2006-10-26 |
Wyeth |
Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
|
WO2006116016A2
(en)
|
2005-04-21 |
2006-11-02 |
The Regents Of The University Of California |
Molecular determinants of egfr kinase inhibitor response in glioblastoma
|
TW200716129A
(en)
|
2005-04-28 |
2007-05-01 |
Wyeth Corp |
Micronized tanaproget, compositions, and methods of preparing the same
|
BRPI0609957A2
(pt)
|
2005-05-12 |
2010-05-11 |
Pfizer |
uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer
|
BRPI0610147A2
(pt)
|
2005-05-25 |
2010-06-01 |
Wyeth Corp |
método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
|
CA2608394A1
(en)
|
2005-05-25 |
2006-11-30 |
Wyeth |
Methods of preparing 3-cyano-quinolines and intermediates made thereby
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
MX2008000666A
(es)
|
2005-07-15 |
2008-03-13 |
Wyeth Corp |
Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato.
|
WO2007015569A1
(ja)
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
CA2624613A1
(en)
|
2005-10-05 |
2007-04-12 |
Astrazeneca Uk Limited |
Method to predict or monitor the response of a patient to an erbb receptor drug
|
US20110052570A1
(en)
|
2005-10-26 |
2011-03-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
PE20071042A1
(es)
|
2005-11-04 |
2007-10-12 |
Wyeth Corp |
Producto farmaceutico que comprende temsirolimus y malato de sunitinib
|
EP3488866A1
(en)
|
2005-11-04 |
2019-05-29 |
Wyeth LLC |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
JP2009515852A
(ja)
|
2005-11-11 |
2009-04-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Egfr/her2インヒビターを含む癌の組み合わせ治療
|
WO2007059821A1
(en)
|
2005-11-24 |
2007-05-31 |
Aicuris Gmbh & Co. Kg |
Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
|
AU2006331688A1
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Oral formulations comprising tigecycline
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
MX2008014608A
(es)
|
2006-05-18 |
2009-03-31 |
Molecular Profiling Inst Inc |
Sistema y metodo para determinar la intervencion medica individualizada para un estado de enfermedad.
|
US20100113299A1
(en)
|
2008-10-14 |
2010-05-06 |
Von Hoff Daniel D |
Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
EP2032989B2
(en)
|
2006-06-30 |
2015-10-28 |
Merck Sharp & Dohme Corp. |
Igfbp2 biomarker
|
PT2068880E
(pt)
|
2006-09-18 |
2012-07-12 |
Boehringer Ingelheim Int |
Método para tratamento do cancro apresentando mutações no egfr
|
US8252749B2
(en)
|
2006-09-28 |
2012-08-28 |
Follica, Inc. |
Methods, kits, and compositions for generating new hair follicles and growing hair
|
EP2073823A1
(en)
|
2006-10-13 |
2009-07-01 |
Medigene AG |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
US20100143340A1
(en)
|
2006-12-13 |
2010-06-10 |
Schering Corporation |
Methods and compositions for treating cancer
|
NZ578329A
(en)
|
2006-12-13 |
2012-05-25 |
Schering Corp |
Igf1r inhibitors for treating cancer
|
CN101678022A
(zh)
|
2006-12-21 |
2010-03-24 |
弗特克斯药品有限公司 |
可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
|
PE20081632A1
(es)
|
2007-01-12 |
2008-12-10 |
Wyeth Corp |
Composiciones de tableta en tableta
|
CN104043123B
(zh)
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
PE20081734A1
(es)
|
2007-02-01 |
2009-01-19 |
Takeda Pharmaceutical |
Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
US8715665B2
(en)
|
2007-04-13 |
2014-05-06 |
The General Hospital Corporation |
Methods for treating cancer resistant to ErbB therapeutics
|
EP2145188A4
(en)
|
2007-04-19 |
2010-06-30 |
Wellstat Biologics Corp |
DETECTION OF HER2 / NEU PROTEIN FROM UNISISIONED CIRCULATING CANCER CELLS AND TREATMENT
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
EP2200431B1
(en)
|
2007-09-10 |
2016-07-20 |
Boston Biomedical, Inc. |
Novel compositions and methods for cancer treatment
|
JP2010540459A
(ja)
|
2007-09-24 |
2010-12-24 |
トラガラ ファーマシューティカルズ,インク. |
Cox‐2阻害薬及びegfr[erbb1]とher‐2[erbb2]の二重阻害薬を用いた癌を治療するための併用療法
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
WO2009055343A2
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
CA2704006A1
(en)
|
2007-11-05 |
2009-05-14 |
Puretech Ventures |
Methods, kits, and compositions for administering pharmaceutical compounds
|
MX2010006854A
(es)
|
2007-12-18 |
2010-09-09 |
Schering Corp |
Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
WO2009108637A1
(en)
|
2008-02-25 |
2009-09-03 |
Prometheus Laboratories, Inc. |
Drug selection for breast cancer therapy using antibody-based arrays
|
US20100081632A1
(en)
|
2008-03-06 |
2010-04-01 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
CA2718918A1
(en)
|
2008-03-25 |
2009-11-26 |
Schering Corporation |
Methods for treating or preventing colorectal cancer
|
EP2977468B1
(en)
|
2008-03-27 |
2019-06-19 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in pulmonary arterial hypertension
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
US20110182888A1
(en)
|
2008-04-08 |
2011-07-28 |
Peter Ordentlich |
Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
|
MX2010011437A
(es)
|
2008-04-18 |
2010-12-20 |
Reata Pharmaceuticals Inc |
Moduladores antioxidantes de inflamacion: derivados del acido oleanolico con saturacion en el anillo c.
|
KR20110010611A
(ko)
|
2008-04-18 |
2011-02-01 |
리타 파마슈티컬스 잉크. |
산화방지성 염증 조절제 c-17 일치된 올레아놀산 유도체
|
US8071632B2
(en)
|
2008-04-18 |
2011-12-06 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
DK2276493T3
(da)
|
2008-04-18 |
2019-01-02 |
Reata Pharmaceuticals Inc |
Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
|
CA2721665C
(en)
|
2008-04-18 |
2017-01-24 |
Reata Pharmaceuticals, Inc. |
Compounds including an anti-inflammatory pharmacore and methods of use
|
MX2010012064A
(es)
|
2008-05-05 |
2010-12-06 |
Schering Corp |
Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
US20090312360A1
(en)
|
2008-06-17 |
2009-12-17 |
Wyeth |
Antineoplastic Combinations Containing HKI-272 and Vinorelbine
|
ES2449396T3
(es)
|
2008-07-22 |
2014-03-19 |
Trustees Of Dartmouth College |
Cianoenonas monocíclicas y métodos de uso de las mismas
|
JP5681108B2
(ja)
|
2008-08-04 |
2015-03-04 |
ワイス・エルエルシー |
4−アニリノ−3−シアノキノリンとカペシタビンの抗新生物薬の組合せ
|
US20100069340A1
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
JP2012508244A
(ja)
|
2008-11-07 |
2012-04-05 |
エンゾン ファーマシューティカルズ,インコーポレーテッド |
ErbB−3(HER3)選択的併用療法
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
EP2393364A4
(en)
|
2009-02-04 |
2013-03-13 |
Bipar Sciences Inc |
TREATMENT OF LUNG CANCER WITH A PARP INHIBITOR IN COMBINATION WITH A GROWTH FACTOR INHIBITOR
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
AU2010221818A1
(en)
|
2009-03-11 |
2011-10-06 |
Auckland Uniservices Limited |
Prodrug forms of kinase inhibitors and their use in therapy
|
CA2755789C
(en)
|
2009-04-06 |
2016-01-19 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
CN102482277B
(zh)
|
2009-05-05 |
2017-09-19 |
达纳-法伯癌症研究所有限公司 |
表皮生长因子受体抑制剂及治疗障碍的方法
|
CA2766067A1
(en)
|
2009-07-02 |
2011-01-06 |
Wyeth Llc |
3-cyanoquinoline tablet formulations and uses thereof
|
US20120135952A1
(en)
|
2009-07-17 |
2012-05-31 |
Hanall Biopharma Co., Ltd. |
Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
|
WO2011008053A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
N,n-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
WO2011025271A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
WO2011025269A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
KR20110021691A
(ko)
|
2009-08-25 |
2011-03-04 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
AU2010302961A1
(en)
|
2009-10-01 |
2012-04-19 |
Csl Limited |
Method of treatment of philadelphia chromosome positive leukaemia
|
ES2729677T3
(es)
|
2009-11-09 |
2019-11-05 |
Wyeth Llc |
Esferoides de fármacos recubiertos y sus usos para eliminar o reducir condiciones, como la emesis y la diarrea
|
CN102724970B
(zh)
|
2009-11-09 |
2014-06-25 |
惠氏有限责任公司 |
来那替尼马来酸盐的片剂制剂
|
ES2655737T3
(es)
|
2009-11-13 |
2018-02-21 |
Daiichi Sankyo Europe Gmbh |
Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3
|
EP2509592A1
(en)
|
2009-12-07 |
2012-10-17 |
Boehringer Ingelheim International GmbH |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
WO2011070499A1
(en)
|
2009-12-11 |
2011-06-16 |
Wyeth Llc |
Phosphatidylinositol-3-kinase pathway biomarkers
|
CA2787048C
(en)
|
2010-01-13 |
2021-06-22 |
Wyeth Llc |
A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor
|